Valuation: Novogenia AG

Market Cap 80.4M 91.76M 74.64M 68.59M 129M 8.85B 131M 889M 348M 4.33B 344M 337M 14.97B P/E 2025
155x
P/E 2026 * -13.1x
Enterprise Value 24.3M 27.73M 22.56M 20.73M 39.06M 2.68B 39.64M 269M 105M 1.31B 104M 102M 4.52B EV / Sales 2025
0.85x
EV / Sales 2026 * 1.2x
Free-Float
42.5%
Yield 2025 *
6.04%
Yield 2026 * 6.42%
1 day-5.59%
1 week+5.56%
Current month-6.99%
1 month-10.74%
3 months-24.43%
6 months-23.56%
Current year-15.29%
1 week 5.7
Extreme 5.7
7.15
1 month 5.7
Extreme 5.7
7.9
Current year 5.7
Extreme 5.7
12.1
1 year 5.5
Extreme 5.5
12.1
3 years 4.8
Extreme 4.8
12.1
5 years 4.8
Extreme 4.8
12.1
10 years 4.8
Extreme 4.8
12.1
Manager TitleAgeSince
Chief Executive Officer 43 15/03/2021
Director of Finance/CFO - -
Chief Investment Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member - -
Chairman 63 23/06/2021
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-5.59%+5.56% - - 91.76M
+1.79%-5.60%-4.84%+11.84% 46.06B
-0.14%-0.76%+378.26%+583.71% 38.91B
+0.39%+2.79%+8.23%+61.99% 35.57B
-1.54%-4.01%+5.95%-13.03% 33.13B
-0.87%-3.19%-1.27%+29.16% 26.42B
-1.28%-6.20% - - 16.61B
-0.67%-0.21%+10.55%+115.31% 15.08B
-6.32%-4.58%+4.67%+8.37% 14.08B
+0.40%-2.79%+3.58%-31.98% 12.81B
Average -1.35%-2.25%+50.64%+95.67% 26.52B
Weighted average by Cap. -0.38%-2.60%+68.55%+122.71%

Financials

2025 2026 *
Net sales 56M 63.92M 51.99M 47.78M 90.03M 6.17B 91.35M 619M 242M 3.02B 240M 235M 10.43B 57.25M 65.34M 53.15M 48.84M 92.03M 6.3B 93.38M 633M 248M 3.09B 245M 240M 10.66B
Net income 3.3M 3.77M 3.06M 2.82M 5.3M 363M 5.38M 36.5M 14.28M 178M 14.14M 13.83M 614M -6.1M -6.96M -5.66M -5.2M -9.81M -672M -9.95M -67.46M -26.4M -329M -26.13M -25.57M -1.14B
Net Debt -56.1M -64.03M -52.08M -47.86M -90.18M -6.18B -91.51M -620M -243M -3.02B -240M -235M -10.44B -11.6M -13.24M -10.77M -9.9M -18.65M -1.28B -18.92M -128M -50.21M -625M -49.7M -48.63M -2.16B
Logo Novogenia AG
Novogenia AG, formerly Darwin AG, is a Germany-based company, which operates as a biotechnology company. The Company is engaged in production and distribution of personalized dietary supplements and cosmetics. It offers Deoxyribonucleic Acid (DNA), genetic and blood analyses in the lifestyle segment. In addition, test results are primarily used to produce dietary supplements and cosmetics. The Company is active in Pharmaceutical and medical device trading segment as well. It uses artificial intelligence (AI) to create personalized solutions from scientific laboratory analysis data (personalized infusion therapies and In Vitro Fertilization (IVF)/reproductive genetics).
Employees
204
Date Price Change Volume
23/07/26 EUR 6.650 -6.99% 0
22/07/26 EUR 7.150 +13.49% 100
21/07/26 EUR 6.300 -4.55% 0
20/07/26 EUR 6.600 +15.79% 100
17/07/26 EUR 5.700 -9.52% 0
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.700EUR
Average target price
19.38EUR
Spread / Average Target
+189.18%

Annual profits - Rate of surprise